Home Healthcare Pharmaceuticals Liver Disease Therapeutics Market

Liver Disease Therapeutics Market Size, Share & Trends Analysis Report By Product (Vaccines, Antiviral Drugs, Chemotherapy, Targeted Therapy, Immunosuppressants, Corticosteroids, Others), By Disease (Hepatitis, Non-alcoholic Fatty Liver Disease (NAFLD), Hepatic Cancer, Genetic Disorders, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: December 23, 2025 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Liver Disease Therapeutics Market, By Product 2022-2034 (USD MILLION/ Units)
    1. Vaccines
    2. Antiviral Drugs
    3. Chemotherapy
    4. Targeted Therapy
    5. Immunosuppressants
    6. Corticosteroids
    7. Others
  2. Liver Disease Therapeutics Market, By Disease 2022-2034 (USD MILLION/ Units)
    1. Hepatitis
    2. Non-alcoholic Fatty Liver Disease (NAFLD)
    3. Hepatic Cancer
    4. Genetic Disorders
    5. Others
  3. Regional Liver Disease Therapeutics Market
    1. North America
      1. North America Liver Disease Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
        1. Vaccines
        2. Antiviral Drugs
        3. Chemotherapy
        4. Targeted Therapy
        5. Immunosuppressants
        6. Corticosteroids
        7. Others
      2. North America Liver Disease Therapeutics Market By Disease 2022-2034 (USD MILLION/ Units)
        1. Hepatitis
        2. Non-alcoholic Fatty Liver Disease (NAFLD)
        3. Hepatic Cancer
        4. Genetic Disorders
        5. Others
      3. U.S.
        1. Vaccines
        2. Antiviral Drugs
        3. Chemotherapy
        4. Targeted Therapy
        5. Immunosuppressants
        6. Corticosteroids
        7. Others
        8. Hepatitis
        9. Non-alcoholic Fatty Liver Disease (NAFLD)
        10. Hepatic Cancer
        11. Genetic Disorders
        12. Others
      4. Canada
        1. Vaccines
        2. Antiviral Drugs
        3. Chemotherapy
        4. Targeted Therapy
        5. Immunosuppressants
        6. Corticosteroids
        7. Others
        8. Hepatitis
        9. Non-alcoholic Fatty Liver Disease (NAFLD)
        10. Hepatic Cancer
        11. Genetic Disorders
        12. Others
    2. Europe
      1. Europe Liver Disease Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
        1. Vaccines
        2. Antiviral Drugs
        3. Chemotherapy
        4. Targeted Therapy
        5. Immunosuppressants
        6. Corticosteroids
        7. Others
      2. Europe Liver Disease Therapeutics Market By Disease 2022-2034 (USD MILLION/ Units)
        1. Hepatitis
        2. Non-alcoholic Fatty Liver Disease (NAFLD)
        3. Hepatic Cancer
        4. Genetic Disorders
        5. Others
      3. U.K.
        1. Vaccines
        2. Antiviral Drugs
        3. Chemotherapy
        4. Targeted Therapy
        5. Immunosuppressants
        6. Corticosteroids
        7. Others
        8. Hepatitis
        9. Non-alcoholic Fatty Liver Disease (NAFLD)
        10. Hepatic Cancer
        11. Genetic Disorders
        12. Others
      4. Germany
        1. Vaccines
        2. Antiviral Drugs
        3. Chemotherapy
        4. Targeted Therapy
        5. Immunosuppressants
        6. Corticosteroids
        7. Others
        8. Hepatitis
        9. Non-alcoholic Fatty Liver Disease (NAFLD)
        10. Hepatic Cancer
        11. Genetic Disorders
        12. Others
      5. France
        1. Vaccines
        2. Antiviral Drugs
        3. Chemotherapy
        4. Targeted Therapy
        5. Immunosuppressants
        6. Corticosteroids
        7. Others
        8. Hepatitis
        9. Non-alcoholic Fatty Liver Disease (NAFLD)
        10. Hepatic Cancer
        11. Genetic Disorders
        12. Others
      6. Spain
        1. Vaccines
        2. Antiviral Drugs
        3. Chemotherapy
        4. Targeted Therapy
        5. Immunosuppressants
        6. Corticosteroids
        7. Others
        8. Hepatitis
        9. Non-alcoholic Fatty Liver Disease (NAFLD)
        10. Hepatic Cancer
        11. Genetic Disorders
        12. Others
      7. Italy
        1. Vaccines
        2. Antiviral Drugs
        3. Chemotherapy
        4. Targeted Therapy
        5. Immunosuppressants
        6. Corticosteroids
        7. Others
        8. Hepatitis
        9. Non-alcoholic Fatty Liver Disease (NAFLD)
        10. Hepatic Cancer
        11. Genetic Disorders
        12. Others
      8. Russia
        1. Vaccines
        2. Antiviral Drugs
        3. Chemotherapy
        4. Targeted Therapy
        5. Immunosuppressants
        6. Corticosteroids
        7. Others
        8. Hepatitis
        9. Non-alcoholic Fatty Liver Disease (NAFLD)
        10. Hepatic Cancer
        11. Genetic Disorders
        12. Others
      9. Nordic
        1. Vaccines
        2. Antiviral Drugs
        3. Chemotherapy
        4. Targeted Therapy
        5. Immunosuppressants
        6. Corticosteroids
        7. Others
        8. Hepatitis
        9. Non-alcoholic Fatty Liver Disease (NAFLD)
        10. Hepatic Cancer
        11. Genetic Disorders
        12. Others
      10. Benelux
        1. Vaccines
        2. Antiviral Drugs
        3. Chemotherapy
        4. Targeted Therapy
        5. Immunosuppressants
        6. Corticosteroids
        7. Others
        8. Hepatitis
        9. Non-alcoholic Fatty Liver Disease (NAFLD)
        10. Hepatic Cancer
        11. Genetic Disorders
        12. Others
      11. Rest of Europe
        1. Vaccines
        2. Antiviral Drugs
        3. Chemotherapy
        4. Targeted Therapy
        5. Immunosuppressants
        6. Corticosteroids
        7. Others
        8. Hepatitis
        9. Non-alcoholic Fatty Liver Disease (NAFLD)
        10. Hepatic Cancer
        11. Genetic Disorders
        12. Others
    3. APAC
      1. APAC Liver Disease Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
        1. Vaccines
        2. Antiviral Drugs
        3. Chemotherapy
        4. Targeted Therapy
        5. Immunosuppressants
        6. Corticosteroids
        7. Others
      2. APAC Liver Disease Therapeutics Market By Disease 2022-2034 (USD MILLION/ Units)
        1. Hepatitis
        2. Non-alcoholic Fatty Liver Disease (NAFLD)
        3. Hepatic Cancer
        4. Genetic Disorders
        5. Others
      3. China
        1. Vaccines
        2. Antiviral Drugs
        3. Chemotherapy
        4. Targeted Therapy
        5. Immunosuppressants
        6. Corticosteroids
        7. Others
        8. Hepatitis
        9. Non-alcoholic Fatty Liver Disease (NAFLD)
        10. Hepatic Cancer
        11. Genetic Disorders
        12. Others
      4. Korea
        1. Vaccines
        2. Antiviral Drugs
        3. Chemotherapy
        4. Targeted Therapy
        5. Immunosuppressants
        6. Corticosteroids
        7. Others
        8. Hepatitis
        9. Non-alcoholic Fatty Liver Disease (NAFLD)
        10. Hepatic Cancer
        11. Genetic Disorders
        12. Others
      5. Japan
        1. Vaccines
        2. Antiviral Drugs
        3. Chemotherapy
        4. Targeted Therapy
        5. Immunosuppressants
        6. Corticosteroids
        7. Others
        8. Hepatitis
        9. Non-alcoholic Fatty Liver Disease (NAFLD)
        10. Hepatic Cancer
        11. Genetic Disorders
        12. Others
      6. India
        1. Vaccines
        2. Antiviral Drugs
        3. Chemotherapy
        4. Targeted Therapy
        5. Immunosuppressants
        6. Corticosteroids
        7. Others
        8. Hepatitis
        9. Non-alcoholic Fatty Liver Disease (NAFLD)
        10. Hepatic Cancer
        11. Genetic Disorders
        12. Others
      7. Australia
        1. Vaccines
        2. Antiviral Drugs
        3. Chemotherapy
        4. Targeted Therapy
        5. Immunosuppressants
        6. Corticosteroids
        7. Others
        8. Hepatitis
        9. Non-alcoholic Fatty Liver Disease (NAFLD)
        10. Hepatic Cancer
        11. Genetic Disorders
        12. Others
      8. Taiwan
        1. Vaccines
        2. Antiviral Drugs
        3. Chemotherapy
        4. Targeted Therapy
        5. Immunosuppressants
        6. Corticosteroids
        7. Others
        8. Hepatitis
        9. Non-alcoholic Fatty Liver Disease (NAFLD)
        10. Hepatic Cancer
        11. Genetic Disorders
        12. Others
      9. South East Asia
        1. Vaccines
        2. Antiviral Drugs
        3. Chemotherapy
        4. Targeted Therapy
        5. Immunosuppressants
        6. Corticosteroids
        7. Others
        8. Hepatitis
        9. Non-alcoholic Fatty Liver Disease (NAFLD)
        10. Hepatic Cancer
        11. Genetic Disorders
        12. Others
      10. Rest of Asia-Pacific
        1. Vaccines
        2. Antiviral Drugs
        3. Chemotherapy
        4. Targeted Therapy
        5. Immunosuppressants
        6. Corticosteroids
        7. Others
        8. Hepatitis
        9. Non-alcoholic Fatty Liver Disease (NAFLD)
        10. Hepatic Cancer
        11. Genetic Disorders
        12. Others
    4. Middle East and Africa
      1. Middle East and Africa Liver Disease Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
        1. Vaccines
        2. Antiviral Drugs
        3. Chemotherapy
        4. Targeted Therapy
        5. Immunosuppressants
        6. Corticosteroids
        7. Others
      2. Middle East and Africa Liver Disease Therapeutics Market By Disease 2022-2034 (USD MILLION/ Units)
        1. Hepatitis
        2. Non-alcoholic Fatty Liver Disease (NAFLD)
        3. Hepatic Cancer
        4. Genetic Disorders
        5. Others
      3. UAE
        1. Vaccines
        2. Antiviral Drugs
        3. Chemotherapy
        4. Targeted Therapy
        5. Immunosuppressants
        6. Corticosteroids
        7. Others
        8. Hepatitis
        9. Non-alcoholic Fatty Liver Disease (NAFLD)
        10. Hepatic Cancer
        11. Genetic Disorders
        12. Others
      4. Turkey
        1. Vaccines
        2. Antiviral Drugs
        3. Chemotherapy
        4. Targeted Therapy
        5. Immunosuppressants
        6. Corticosteroids
        7. Others
        8. Hepatitis
        9. Non-alcoholic Fatty Liver Disease (NAFLD)
        10. Hepatic Cancer
        11. Genetic Disorders
        12. Others
      5. Saudi Arabia
        1. Vaccines
        2. Antiviral Drugs
        3. Chemotherapy
        4. Targeted Therapy
        5. Immunosuppressants
        6. Corticosteroids
        7. Others
        8. Hepatitis
        9. Non-alcoholic Fatty Liver Disease (NAFLD)
        10. Hepatic Cancer
        11. Genetic Disorders
        12. Others
      6. South Africa
        1. Vaccines
        2. Antiviral Drugs
        3. Chemotherapy
        4. Targeted Therapy
        5. Immunosuppressants
        6. Corticosteroids
        7. Others
        8. Hepatitis
        9. Non-alcoholic Fatty Liver Disease (NAFLD)
        10. Hepatic Cancer
        11. Genetic Disorders
        12. Others
      7. Egypt
        1. Vaccines
        2. Antiviral Drugs
        3. Chemotherapy
        4. Targeted Therapy
        5. Immunosuppressants
        6. Corticosteroids
        7. Others
        8. Hepatitis
        9. Non-alcoholic Fatty Liver Disease (NAFLD)
        10. Hepatic Cancer
        11. Genetic Disorders
        12. Others
      8. Nigeria
        1. Vaccines
        2. Antiviral Drugs
        3. Chemotherapy
        4. Targeted Therapy
        5. Immunosuppressants
        6. Corticosteroids
        7. Others
        8. Hepatitis
        9. Non-alcoholic Fatty Liver Disease (NAFLD)
        10. Hepatic Cancer
        11. Genetic Disorders
        12. Others
      9. Rest of MEA
        1. Vaccines
        2. Antiviral Drugs
        3. Chemotherapy
        4. Targeted Therapy
        5. Immunosuppressants
        6. Corticosteroids
        7. Others
        8. Hepatitis
        9. Non-alcoholic Fatty Liver Disease (NAFLD)
        10. Hepatic Cancer
        11. Genetic Disorders
        12. Others
    5. LATAM
      1. LATAM Liver Disease Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
        1. Vaccines
        2. Antiviral Drugs
        3. Chemotherapy
        4. Targeted Therapy
        5. Immunosuppressants
        6. Corticosteroids
        7. Others
      2. LATAM Liver Disease Therapeutics Market By Disease 2022-2034 (USD MILLION/ Units)
        1. Hepatitis
        2. Non-alcoholic Fatty Liver Disease (NAFLD)
        3. Hepatic Cancer
        4. Genetic Disorders
        5. Others
      3. Brazil
        1. Vaccines
        2. Antiviral Drugs
        3. Chemotherapy
        4. Targeted Therapy
        5. Immunosuppressants
        6. Corticosteroids
        7. Others
        8. Hepatitis
        9. Non-alcoholic Fatty Liver Disease (NAFLD)
        10. Hepatic Cancer
        11. Genetic Disorders
        12. Others
      4. Mexico
        1. Vaccines
        2. Antiviral Drugs
        3. Chemotherapy
        4. Targeted Therapy
        5. Immunosuppressants
        6. Corticosteroids
        7. Others
        8. Hepatitis
        9. Non-alcoholic Fatty Liver Disease (NAFLD)
        10. Hepatic Cancer
        11. Genetic Disorders
        12. Others
      5. Argentina
        1. Vaccines
        2. Antiviral Drugs
        3. Chemotherapy
        4. Targeted Therapy
        5. Immunosuppressants
        6. Corticosteroids
        7. Others
        8. Hepatitis
        9. Non-alcoholic Fatty Liver Disease (NAFLD)
        10. Hepatic Cancer
        11. Genetic Disorders
        12. Others
      6. Chile
        1. Vaccines
        2. Antiviral Drugs
        3. Chemotherapy
        4. Targeted Therapy
        5. Immunosuppressants
        6. Corticosteroids
        7. Others
        8. Hepatitis
        9. Non-alcoholic Fatty Liver Disease (NAFLD)
        10. Hepatic Cancer
        11. Genetic Disorders
        12. Others
      7. Colombia
        1. Vaccines
        2. Antiviral Drugs
        3. Chemotherapy
        4. Targeted Therapy
        5. Immunosuppressants
        6. Corticosteroids
        7. Others
        8. Hepatitis
        9. Non-alcoholic Fatty Liver Disease (NAFLD)
        10. Hepatic Cancer
        11. Genetic Disorders
        12. Others
      8. Rest of LATAM
        1. Vaccines
        2. Antiviral Drugs
        3. Chemotherapy
        4. Targeted Therapy
        5. Immunosuppressants
        6. Corticosteroids
        7. Others
        8. Hepatitis
        9. Non-alcoholic Fatty Liver Disease (NAFLD)
        10. Hepatic Cancer
        11. Genetic Disorders
        12. Others
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.